On 20 February, the Swiss-based biopharmaceutical company AC Immune announced that its partner Genentech, a member of the Roche group, has started a second Phase II trial of RO7105705 in moderate Alzheimer’s disease (AD). The trial is a Phase II multicenter, randomised, double-blind, placebo-controlled and parallel-group study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of RO7105705 in people with moderate AD. The primary outcomes are change from baseline in both cognitive function (as measured by the Alzheimer's Disease Assessment Scale, Cognitive Subscale, 11-item version) and functional capacities (as measured by the Alzheimer's Disease Cooperative Study-Daily Living Inventory). The company plans to recruit 260 participants with moderate AD. RO7105705 is an anti-Tau monoclonal antibody, also being studied by Genentech in a separate Phase II trial evaluating its efficacy and safety in people with prodromal to mild AD.
Genentech starts a Phase II trial in moderate AD
20/02/2019